Get the Stockscreener App
2.74
1.08%
-0.03
Pre-market:
2.80
0.06
+2.19%
Briacell Therapeutics Corp stock is traded at $2.74, with a volume of 135.28K.
It is down -1.08% in the last 24 hours and down -9.27% over the past month.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
See More
Previous Close:
$2.77
Open:
$2.86
24h Volume:
135.28K
Relative Volume:
0.63
Market Cap:
$23.84M
Revenue:
-
Net Income/Loss:
$-30.98M
P/E Ratio:
-0.2244
EPS:
-12.2116
Net Cash Flow:
$-31.84M
1W Performance:
-11.33%
1M Performance:
-9.27%
6M Performance:
-69.47%
1Y Performance:
-12.18%
1-Day Range:
$2.71
$2.975
1-Week Range:
$2.60
$3.2257
52-Week Range:
$0.61
$14.68
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
2.74 | 23.84M | 0 | -30.98M | -31.84M | -12.21 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
Why Briacell Therapeutics Corp stock is rising today - Wealth Awesome
Why Briacell Therapeutics Corp stock is plummeting today - Wealth Awesome
BCTXZ SEC FilingsBriacell Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan
BCTX Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares Amid Revenue AbsenceROE Trend Analysis - newsline.com
BriaCell (NASDAQ: BCTX) ramps cancer trials but flags going concern risk - Stock Titan
BriaCell receives FDA clearance for breast cancer therapy trial - Investing.com
Immunotherapy Innovations: Increasing Survival in Metastatic Breast Cancer - Investing News Network
BriaCell (NASDAQ: BCTX) completes $4.71M best efforts common share sale - Stock Titan
BriaCell Therapeutics Prices $4.71 Million Share Offering at $3.25; ThinkEquity as Placement Agent - TradingView
Beyond the Lab: Top-Tier Clinical Validation in Biotech Investing - Investing News Network
BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering - Moomoo
BriaCell Therapeutics Closes $4.7 Million Share Offering - marketscreener.com
BriaCell Therapeutics Announces Closing of Offering - Investing News Network
BriaCell Therapeutics (BCTX) raises ~$3.94M net in $3.25 share placement - Stock Titan
What Does BriaCell's Latest Offering Mean for Investors - Kavout
BriaCell Presents Positive Clinical Data at ASCO 2026 - Sahm
BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting - Moomoo
BriaCell Therapeutics Prices $4.7 Million Share Offering - Moomoo
BriaCell Down 9.3% as Prices Offering to Raise US$4.7 Million - marketscreener.com
What Does BriaCell's Latest Offering Mean for Shareholders - Kavout
BriaCell Therapeutics Announces Pricing of Offering - Moomoo
BriaCell Prices Public Offering With Shares at $X and Warrants at $Y - geneonline.com
BriaCell Offering Expected to Close June 2 >BCT.T - Moomoo
BriaCell prices $4.7M share offering to fund cancer immunotherapy development - Pluang
Briacell Therapeutics prices 1.45 million common shares at $3.25 per share - marketscreener.com
BriaCell Plans to Use Proceeds for Working Capital Requirements, General Corporate Purposes, Advancement of Business Objectives >BCT.T - Moomoo
Cancer immunotherapy firm BriaCell raises $4.7M for operations - Stock Titan
MSN Money - MSN
BCTXL Warrants Slip Slightly as Consolidation Continues Near $0.95TICK Divergence - newsline.com
(BCT) Risk-Controlled Trading Report (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Warrants (BCTXL) Slide 3.06% as Momentum Wanes Near $1 ResistanceEMA Signal - newsline.com
BriaCell Therapeutics (BCTX) Surges 6% as Shares Test Key Resistance LevelBlue Chip Entry Points - newsline.com
BriaCell Therapeutics Corp. (BCTX) Stock Price, News, Quote & History - Yahoo Finance
BriaCell (BCTX) Receives Positive Update from Data Safety Monito - GuruFocus
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer - Investing News Network
BCTX - Finviz
BriaCell Says Received Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer - marketscreener.com
Breast cancer trial under FDA Fast Track clears sixth safety review - Stock Titan
BriaCell Therapeutics Q1 2026 Earnings: Narrower-than-Expected EPS Loss Despite No RevenueCrowd Consensus Signals - Newser
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT at ASCO 2026 - Investing News Network
Breast cancer vaccine Bria-IMT shows 16.6-month survival, home-use potential - Stock Titan
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026 - GlobeNewswire
BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026 - GuruFocus
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 - Investing News Network
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 - Investing News Network
BriaCell develops ovarian cancer immunotherapy candidate - Investing.com India
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):